AUS
NZ
UK
CA
USA
IND
Highlights
- Prescient Therapeutics (ASX:PTX) has initiated a Phase 2a study of PTX-100.
- The study will evaluate the efficacy and safety of PTX-100 in CTCL patients.
- Sites across Australia, the USA, and Europe are set to participate.
Prescient Therapeutics (ASX:PTX) has recently marked a significant advancement in the treatment of Cutaneous T-Cell Lymphoma (CTCL) by initiating the first Site Initiation Visit (SIV) for its Phase 2a clinical study of PTX-100. This open-label study is designed to explore the effectiveness and safety of PTX-100 across two dosage levels in approximately 40 patients, with a primary focus on efficacy.
The initiation of this study highlights the progress of (ASX:PTX) in the development of potential treatments for diseases with critical needs. The study will play a crucial role in understanding PTX-100's impact on patients who have relapsed or are refractory to existing treatments for CTCL, a niche yet challenging area in cancer therapy.
With the successful completion of the SIV, (ASX:PTX) is now poised to further expand its research across multiple international locations. The study will soon include sites in Australia, the USA, and Europe, broadening the scope and impact of the research. This expansion is part of (ASX:PTX)'s strategic plan to integrate diverse patient data and enhance the robustness of the study results.
James McDonnell, CEO of Prescient Therapeutics, expressed enthusiasm about reaching this crucial milestone, highlighting the company’s commitment to advancing a potentially transformative treatment for CTCL. "The completion of the first SIV for this study is a key milestone in our development of PTX-100 as a potential CTCL treatment. It is the first of multiple sites that will be initiated in Australia, the USA, and Europe," McDonnell stated.
Adding to the company’s leadership excitement, Chief Medical Officer Dr. Marissa Lim shared her thoughts on the significance of this achievement. "It is very exciting to reach this milestone of opening the first study site for the Phase 2a study of PTX-100 at the Epworth Freemasons Haematology Clinical Trial Unit," she said. Renowned CTCL specialist Professor Miles Prince, AM, will lead the study, further cementing its potential to make significant advancements in the field.
As (ASX:PTX) looks forward to the upcoming weeks, the next anticipated milestone is the First Patient In and Dosed (FPID). This step will be crucial in moving closer to a deeper understanding and potentially improving the lives of those affected by CTCL.
Through diligent planning and a focus on innovative treatments, Prescient Therapeutics continues to demonstrate its role as a leader in the pharmaceutical industry, with the ongoing PTX-100 study serving as a testament to its commitment to addressing unmet medical needs in oncology.
